Antileukemic Activity of Lysophosphatidic Acid Acyltransferase- Inhibitor CT32228 in Chronic Myelogenous Leukemia Sensitive and Resistant to Imatinib

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-06-0140
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Characteristics of Dasatinib- And Imatinib-Resistant Chronic Myelogenous Leukemia Cells

Clinical Cancer Research
Cancer ResearchOncology
2008English

Suboptimal Responses to Imatinib in Chronic Myelogenous Leukemia

Clinical Journal of Oncology Nursing
Oncology
2009English

An Analysis of Strategic Treatment Interruptions During Imatinib Treatment of Chronic Myelogenous Leukemia With Imatinib-Resistant Mutations

Mathematical Biosciences
StatisticsGeneticsProbabilityMolecular BiologyBiochemistryApplied MathematicsMicrobiology SimulationImmunologyBiological SciencesMedicineAgriculturalModeling
2015English

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Cancer Research
Cancer ResearchOncology
2004English

Increased Cortical Bone Mineralization in Imatinib Treated Patients With Chronic Myelogenous Leukemia

Haematologica
Hematology
2008English

Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments

2019English

Efficacy of the Dual PI3K and mTOR Inhibitor NVP-BEZ235 in Combination With Imatinib Mesylate Against Chronic Myelogenous Leukemia Cell Lines

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2017English

Chronic Myelogenous Leukemia

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2012English

Lysophosphatidic Acid Acyltransferase Beta Regulates mTOR Signaling

PLoS ONE
Multidisciplinary
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy